價格 | ¥1370 | ¥3450 | ¥4910 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:帕立骨化醇 | 英文名稱:Paricalcitol |
CAS:131918-61-1 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.5% | 產(chǎn)品類別: 抑制劑 |
貨號: TQ0200 |
Name | Paricalcitol |
Description | Paricalcitol is a vitamin D receptor agonist. It is used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. |
Animal Research | After TAC or sham surgery, a subset of the mice is treated with paricalcitol which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice were intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday, and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10) [2]. |
In vitro | Paricalcitol (30 nM; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells [1]. |
In vivo | Paricalcitol (300 ng/kg/day) significantly decreases Tau and prevents LV dysfunction in mice. It reduces mRNA expression of ANP, fibronectin and collagen III in the TAC-pari mice [2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : Insoluble Ethanol : 12 mg/mL (38.8 mM), Sonication is recommended. DMSO : 95 mg/mL (228.02 mM), Sonication is recommended. |
Keywords | Vitamin D receptor | Vitamin D | Inhibitor | VD/VDR | Paricalcitol | inhibit |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥529 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-12-28 | |
詢價 |
VIP2年
|
山東迪貝克生物工程有限公司
|
2024-12-28 | |
詢價 |
VIP3年
|
普善實(shí)業(yè)(陜西)有限公司
|
2024-12-27 | |
詢價 |
VIP1年
|
湖北鴻福達(dá)生物科技有限公司
|
2024-12-27 | |
詢價 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-27 | |
詢價 |
VIP3年
|
泰安市江舟生物科技有限公司
|
2024-12-27 | |
詢價 |
VIP7年
|
河南開研生物科技有限公司
|
2024-12-27 | |
詢價 |
VIP11年
|
深圳振強(qiáng)生物技術(shù)有限公司
|
2024-12-27 | |
¥5000 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-27 | |
¥20000 |
VIP1年
|
武漢普世達(dá)生物科技有限公司
|
2024-12-27 |